

Jean-Luc Raoul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/624961/publications.pdf>

Version: 2024-02-01

40
papers

23,704
citations

489802

18
h-index

312153

41
g-index

44
all docs

44
docs citations

44
times ranked

25816
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. <i>Cancers</i> , 2022, 14, 1156.	1.7	6
2	Survival after cytoreductive surgery for peritoneal metastases in colorectal cancer patients: Does a history of resected liver metastases worsen the prognosis?. <i>European Journal of Surgical Oncology</i> , 2022, 48, 803-809.	0.5	0
3	COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19). <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210901.	0.6	3
4	Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 248.	1.7	4
5	Retrorectal Mucinous Adenocarcinoma Arising from a Tailgut Cyst: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 147-151.	0.3	4
6	Transient Vision Loss – A Rare Oxaliplatin-Induced Ophthalmologic Side Effect: A Report of Two Cases. <i>Case Reports in Oncology</i> , 2021, 14, 483-486.	0.3	2
7	Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. <i>JAMA Network Open</i> , 2021, 4, e2113739.	2.8	19
8	Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients – First Results from the PAPESCO-19 Cohort Study. <i>Cancers</i> , 2021, 13, 3389.	1.7	5
9	Intra-abdominal recurrence from colorectal carcinoma: Differences and similarities between local and peritoneal recurrence. <i>Surgical Oncology</i> , 2020, 32, 23-29.	0.8	2
10	Prognostication of HCC under sorafenib: Is it always possible?. <i>Liver International</i> , 2020, 40, 1241-1243.	1.9	1
11	A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. <i>European Journal of Cancer</i> , 2020, 140, 37-44.	1.3	37
12	Significance of lymph node involvement in local recurrence of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2019, 120, 722-728.	0.8	4
13	BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report. <i>Case Reports in Oncology</i> , 2019, 12, 426-429.	0.3	0
14	Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2019, 6, HEP11.	4.2	24
15	Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. <i>Liver Cancer</i> , 2019, 8, 457-467.	4.2	42
16	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. <i>Journal of Hepatology</i> , 2017, 66, 1166-1172.	1.8	178
17	A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study. <i>Supportive Care in Cancer</i> , 2017, 25, 2715-2722.	1.0	4
18	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1467-1476.	0.9	23

#	ARTICLE	IF	CITATIONS
19	To TACE or not to TACE? Lessons from a negative trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 541-543.	3.7	2
20	An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value. <i>PLoS ONE</i> , 2017, 12, e0177971.	1.1	7
21	Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 15-19.	0.6	10
22	Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. <i>Case Reports in Oncology</i> , 2016, 9, 154-157.	0.3	1
23	Solid Pseudopapillary Tumor of the Pancreas: One Case with a Metastatic Evolution in a Caucasian Woman. <i>Case Reports in Oncology</i> , 2015, 8, 405-408.	0.3	3
24	Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema. <i>Case Reports in Oncology</i> , 2014, 7, 825-827.	0.3	11
25	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014, 3, 439-450.	4.2	21
26	High Prognostic Value of ¹⁸ F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1786-1790.	2.8	153
27	Bazex Syndrome Revealing a Gastric Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 285-287.	0.3	7
28	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3517-3524.	0.8	675
29	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3509-3516.	0.8	544
30	Why is pancreatic cancer difficult to treat in the elderly?. <i>Aging Health</i> , 2012, 8, 301-307.	0.3	2
31	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012, 56, 1080-1088.	1.8	109
32	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	1.8	736
33	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 147-156.	2.0	250
34	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1817-1825.	13.9	6,140
35	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2011, 364, 501-513.	13.9	2,216
36	Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 1973-1983.	3.2	142

#	ARTICLE	IF	CITATIONS
37	Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). <i>Gut</i> , 2010, 59, 1527-1534.	6.1	70
38	Predictive Value of ¹⁸ F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 858-864.	2.8	224
39	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
40	Acrokeratosis Paraneoplastica (Bazexâ€™™ Syndrome) Associated With Metastatic Squamous Cell Esophageal Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5128-5129.	0.8	9